Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2026-05-11 @ 7:49 AM
Study NCT ID:
NCT04843267
Status:
UNKNOWN
Last Update Posted:
2021-04-13
First Post:
2021-04-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Sponsor:
Organization: